Medicus Pharma inks Pfizer CD228V co-development and global license deal
Medicus Pharma entered a co-development and license agreement with Pfizer for CD228V, a worldwide, early clinical-stage CD228-targeting antibody-drug conjugate. The deal grants an exclusive, sublicensable patent license and includes $12M upfront plus $1B+ milestones.
Medicus Pharma entered a Co-Development and License Agreement with Pfizer to advance CD228V, an early clinical-stage antibody-drug conjugate targeting CD228, worldwide.
The deal provides Medicus an exclusive, sublicensable license to Pfizer’s patents for development, manufacturing, and commercializ…